IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment
IGC Pharma introduced PRISM, a new application layer built on its patent-pending MINT-AD Alzheimer's AI platform, aimed at risk stratification, cognitive monitoring, and clinical trial optimization. The company says it is evaluating B2B, B2B2C, and direct-to-consumer commercialization pathways, but no contracts, licensing deals, or revenue commitments have been announced.
Key figures
- Phase Of Trial
- Phase 2
- Aha time reduction
- 28 hours to 2.5 hours (~90%)
- Calma participants
- 168
- Dementia cost estimate
- $1.3 trillion annually, ~$2.8 trillion by 2030
- Early alzheimers pathology est
- 400 million individuals worldwide
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.